

## The transcriptional repressor SmvR is important for chlorhexidine decreased susceptibility in Enterobacter cloacae complex

François Guérin, François Gravey, Patrick Plesiat, Marion Aubourg, Racha Beyrouthy, Richard Bonnet, Vincent Cattoir, Jean-Christophe Giard

### ▶ To cite this version:

François Guérin, François Gravey, Patrick Plesiat, Marion Aubourg, Racha Beyrouthy, et al.. The transcriptional repressor SmvR is important for chlorhexidine decreased susceptibility in Enter-obacter cloacae complex. Antimicrobial Agents and Chemotherapy, 2019, 64 (1), pp.e01845-19. 10.1128/AAC.01845-19. hal-02397671

## HAL Id: hal-02397671 https://univ-rennes.hal.science/hal-02397671

Submitted on 11 Dec 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	The transcriptional repressor SmvR is important for chlorhexidine
2	decreased susceptibility in Enterobacter cloacae complex
3	
4	Running title: ECC clinical isolates, MFS efflux pump repressor, chlorhexidine
5	
6	François Guérin <sup>1,2*</sup> , François Gravey <sup>1</sup> , Patrick Plésiat <sup>3,4</sup> , Marion Aubourg <sup>5</sup> , Racha
7	Beyrouthy <sup>6</sup> , Richard Bonnet <sup>6</sup> , Vincent Cattoir <sup>7,8</sup> , Jean-Christophe Giard <sup>5</sup>
8	
9	<sup>1</sup> Normandie University, UNICAEN, UNIROUEN, GRAM 2.0, 14000 Caen F-14033, France
10	<sup>2</sup> Caen University Hospital, Department of Clinical Microbiology, Caen F-14033, France*
11	<sup>3</sup> Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier
12	Universitaire de Besançon, Besançon, France.
13	<sup>4</sup> UMR6249 CNRS Chrono-Environnement, Université de Franche-Comté, Besançon, France.
14	<sup>5</sup> University of Caen Normandie, Unité de Recherche Risques Microbiens (U2RM), Caen F-
15	35033, France
16	<sup>6</sup> Clermont-Ferrand, University Hospital, Department of Clinical Microbiology, Clermont-
17	Ferrand F-63003 France
18	<sup>7</sup> Rennes University Hospital, Department of Clinical Microbiology & CNR de la Résistance
19	aux Antibiotiques, Rennes F-35033, France
20	<sup>8</sup> Inserm U1230-Biochimie pharmaceutique, Rennes University, Rennes F-35033, France
21	*Correspondence: Mailing address: Dr. François Guérin, CHU de Caen, Service de
22	Microbiologie, Av. de la Côte de Nacre, 14033 Caen Cedex 9, France. +33-2-31-06-45-72,
23	Fax: +33-2-31-06-45-73, E-mail: guerin-f@chu-caen.fr
24	Keywords: E. cloacae; ECC; Efflux; MFS; Chlorhexidine
25	
26	Word count: abstract = 250 words; text = 2,716 words; 1 Table; 4 Figures; 25 References

#### 28 ABSTRACT

Major Facilitator Superfamily (MFS) efflux pumps have been shown to be important for 29 bacterial cells to cope with biocides such as chlorhexidine (CHX), a widely used molecule in 30 hospital settings. In this work, we evaluated the role of two genes: *smvA* and *smvR* in CHX 31 resistance in *Enterobacter cloacae* complex (ECC). *smvA* encodes an MFS pump whereas 32 smvR, located upstream of smvA, codes for a TetR-type transcriptional repressor. To this aim, 33 we constructed corresponding deletion mutants from the ATCC 13047 strain (MIC = 2 mg/L) 34 as well as strains overexpressing smvA or smvR both in ATCC 13047 and three clinical 35 isolates exhibiting elevated MICs of CHX (16-32 mg/L). Determination of MICs revealed that 36 smvA played a modest role in CHX resistance, contrarily to smvR that modulated the ability of 37 ECC to survive in the presence of CHX. In clinical isolates, the overexpression of smvR 38 significantly reduced MICs of CHX (2-8 mg/L). Sequences analyses of *smvR* and promotor 39 regions pointed out substitutions in conserved regions. Moreover, transcriptional studies 40 revealed that SmvR acted as a repressor of *smvA* expression even if no quantitative correlation 41 42 between the level of *smvA* mRNA and MICs of CHX could be observed. On the other hand, overproduction of *smvA* was able to complement the lack of the major resistance-nodulation-43 cell division (RND) superfamily efflux pump AcrB and restored resistance to ethidium 44 bromide and acriflavine. Although SmvA could efflux biocides such as CHX, other actors, of 45 which the expression is under SmvR control, should play critical role in ECC. 46

#### 48 INTRODUCTION

Biocidal agents are wildly used to limit the spread of antibiotic-resistant bacteria in hospitals. 49 However, numerous compounds that help for disinfection in healthcare may enhance the risk 50 of emergence of antibiotic resistance, especially during a long period of low-level exposure 51 (1). The bisguanide chlorhexidine (CHX) is frequently used in healthcare environments for 52 hospitalized patients skin (catheter maintenance) or mucous (mouthwash) disinfection (2). 53 Bacterial decreased susceptibility to biocides involve one or several mechanisms such as 54 activation of efflux pumps, modification or overexpression of targets (3). For example, some 55 efflux pumps as AceI in Acinetobacter baumannii and CepA in Klebsiella pneumoniae have 56 been described to be involved in decrease of CHX susceptibility (4,5). Moreover, Wand et al. 57 demonstrated that increased tolerance to CHX in K. pneumoniae was associated with an 58 overexpression of the *smvA* gene encoding an efflux pump belonging to the major facilitator 59 superfamily (MFS) and that the latter gene was under the control of the TetR-family 60 transcriptional regulator SmvR (6). 61

62 The species of the Enterobacter genus, mainly E. cloacae complex (ECC) and E. aerogenes, are responsible for 7% of infections among patients hospitalized in intensive care units (ICUs) 63 (7). Actually, ECC is composed of 14 clusters (designated C-I to C-XIV) among which three 64 (C-III, VI, and VIII) are the most frequently recovered from human clinical specimens (8,-65 10). In addition, ECC are capable of 'escaping' the antibacterial action of several antibiotics 66 and were classified among the multidrug-resistant (MDR) ESKAPE pathogens (Enterococcus 67 faecium, Staphylococcus aureus, K. pneumoniae, A. baumannii, Pseudomonas aeruginosa 68 and Enterobacter spp.) (11). 69

The purpose of the study was 1) to evaluate the *in vitro* antibiotic and biocide susceptibilities of the ATCC 13047 reference strain and clinical strains belonging to ECC, 2) to characterize the role of ECL\_1895/ECL\_01896 locus (homologous to *smvAR*) by constructing the corresponding knock-out mutants and overexpressing strains. Our data revealed that the
SmvR-like regulator played an important role in CHX resistance and no correlation was
observed between MICs of CHX and transcriptional levels of *smvA*.

76

#### 77 MATERIALS AND METHODS

#### 78 Strains, media and growth conditions

Bacterial strains and plasmids used in this study are listed in Table S1. The reference strain 79 was E. cloacae subp. cloacae ATCC 13047 [ECL13047] for which the genome sequence is 80 available (GenBank accession numbers CP002886, FP929040 and AGSY0000000) and 81 belonging to the cluster XI (12). Escherichia coli and E. cloacae strains were cultured with 82 shaking (200 rpm) at 37°C in Luria-Bertani (LB) medium. Besides the reference strain, three 83 unrelated ECC clinical isolates (belonging to cluster III, VI and VIII) with different CHX 84 85 resistance levels collected from the University Hospital of Caen (France) were included in the study. Identification at the species level was performed by using the MALDI-TOF mass 86 87 spectrometry method (Microflex, Bruker Daltonik, Bremen, Germany) while delineation to the cluster membership was obtained regarding *hsp60* gene sequence as previously described 88 (8). 89

#### 90 Drug susceptibility testing

MICs of CHX, crystal violet (CV), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BL), ethidium Bromide (EtBr), acriflavine (ACR), cefotaxime (CTX), gentamicin (GEN), amikacin (AMK), chloramphenicol (CHL), erythromycin (ERY), norfloxacin (NOR) and tetracycline (TET) were determined by the broth microdilution (BMD) reference method using the cation-adjusted Mueller-Hinton broth (CA-MHB) (Becton-Dickinson, Le Pont de Claix, France), in accordance with EUCAST guidelines (http://www.eucast.org/). MICs of CHX was also determined by BMD with or without reserpine (20 mg/L). The minimal bactericidal concentration (MBC) was determined only for CHX by sub-culturing the last tube
showing visible growth and all the tubes in which there was no growth on already prepared
plates containing Mueller Hinton agar medium. The plates were then incubated at 37 °C for
24 h and the lowest concentration showing no growth was taken as the MBC.

#### 102 **Construction of the knockout mutants**

Disruption of the genes encoding MFS transporter (*smvA*) and its putative TetR regulator (*smvR*) was performed using the method previously described using the Red helper plasmid pKOBEG (13,-15). The primers used in the study are reported in Table S2.

# 106 Construction of multicopy plasmid library containing putative efflux pump or regulator 107 ORFs

-----

The regulator and the MFS efflux pump encoding genes (smvA/smvR) including their own 108 promoters were amplified by PCR using primers listed in Table S2. Each amplicon was then 109 110 TA-cloned into the overexpression plasmid, pBAD202 (low-copy number plasmid: ~20 copies/cell) Directional TOPO (Invitrogen, Villebon sur Yvette, France). E. coli TOP-10 cells 111 112 (Invitrogen) carrying pBAD202 recombinants containing correctly oriented inserts were selected on LB plates with 40 mg/L of kanamycin. After purification, each plasmid carrying 113 the regulator or MFS efflux pump encoding genes was used to transform ECC ATCC 13047 114 strain and clinical isolates (Table S1). 115

#### 116 **RNA extraction and qRT-PCR**

Total RNAs were extracted from bacterial cells grown to the late-exponential phase in presence or not of CHX (1/4 MIC) by using the Direct-Zol RNA mini-prep kit (Zymo Research, Irvine, CA). Residual chromosomal DNA was removed by treating samples with the TURBO DNA-*free* kit (Life Technologies, Saint-Aubin, France). Samples were quantified using the NanoDrop One spectrophotometer (Thermo Fisher Scientific, Courtaboeuf, France). cDNA was synthesized from total RNAs (~1 µg) using the QuantiTect reverse transcription kit (Qiagen) according to the manufacturer's instructions. For each RNA sample, transcript levels were determined by the DeltaCt method using the expression of the corresponding *rpoB* gene as a housekeeping control gene from the same RNA extraction (Table S2). The expression ratio were determined by comparison with the level of transcription measured for the ATCC 13047 strain. Experiments were performed at least three times and Student t-test was performed. *p*-values less than 0.05 were considered as statistically significant.

#### 129 WGS and bioinformatic analysis

Genomic DNA was isolated from ECC isolates using the using the Quick-DNA 130 fungal/bacterial miniprep kit (Zymo Research, Irvine, CA) according to the manufacturer's 131 recommendations. After DNA shearing, the DNA libraries were prepared using the NEBNext 132 Ultra DNA library prep kit for Illumina (New England Biolabs, Ipswich, MA) and sequenced 133 as paired-end reads (2 x 300 bp) using an Illumina MiSeq platform and the MiSeq reagent kit 134 135 version 3. The Illumina reads were trimmed using Trimmomatic (Bolger Bioinformatics 2014), quality filtered with the Fastx-toolkit (http://hannonlab.cshl.edu/fastx\_toolkit/) and 136 then assembled using the SPAdes and plasmidSPAdes softwares (16,17). The nucleotide 137 sequences were also submitted to ResFinder server (www.genomicepidemiology.org/) to 138 identify acquired antimicrobial resistance genes (18). The presence of qac and teh genes was 139 exanimed using Blast software on a home-made database containing 59 genes recovered from 140 NCBI database. These genes are listed in Table S3. 141

- 142
- 143

#### 144 **RESULTS AND DISCUSSION**

#### 145 ECL\_01896 (*smvA*) is a putative efflux pump involved in CHX decreased susceptiblity

146 One of the main mechanism underlying CHX decreased susceptibility in *Enterobacteriaceae* 

147 is related to the expression of efflux pumps allowing the expulsion of antiseptic molecules

(19). The gene coding for the quaternary ammonium (qac) compound efflux SMR (Small 148 Multidrug Resistance) transporter QacE delta 1 has been recovered among 68% of CHX 149 decreased susceptibility extended-spectrum β-lactamase producing (EBSL) E. cloacae clinical 150 isolates (20). However, the prevalence of this gene, located into an integron, did not seem to 151 correlate with the decreased susceptibility to biocides in MDR enterobacterial species 152 including E. cloacae and no qac gene was recovered in any strain of this study (21). Analysis 153 of the genome of E. cloacae ATCC 13047 and that of clinical isolates ECLJO\_031, 154 ECLJO\_32 and ECLJO\_38, allowed us to identify a locus (ECL\_01896, henceforth named 155 smvA) encoding a major facilitator transporter of the MFS family (12). This last showed 91% 156 and 72% amino acid identities with the SmvA protein of Klebsiella aerogenes and of K. 157 pneumoniae, respectively (data not shown). To evaluate the role of this SmvA-like protein, 158 we constructed the smvA deletion mutant strain and showed that the MIC of CHX was 4-fold 159 160 reduced compared to the ATCC 13047 parental strain (0.5 mg/L and 2 mg/L, respectively) (Table 1) indicating that *smvA*-is intrinsically able to efflux CHX in ECC. 161

#### 162 ECL\_01895 (*smvR*) regulates the transcription of *smvA*

Interestingly, the gene ECL 01895 (henceforth named smvR), located upstream smvA and 163 divergently transcribed, coded for a TetR-family transcriptional regulator homologous to 164 smvR of K. aerogenes and K. pneumoniae. Recently, Wand et al. showed that SmvR acted as 165 a repressor of the *smvA* transcription and mutation into the sequence of the regulator was 166 correlated with the CHX adaptation (22). Unexpectedly, in ECC ATCC 13047 strain that 167 exhibited a low MIC of CHX (2 mg/L), the total deletion of *smvR* led to an overexpression of 168 *smvA* by 6-fold but only modestly increased CHX MIC (4 mg/L) (p < 0.05) (Figure 1, Table 169 170 1). On the other hand, CHX susceptibility of the ECL JO04 strain, genetically very close to the susceptible strain ECL\_JO40) but totally deleted of both smvA and smvR, was more 171 reduced (0.25 mg/L) than single *smvA* or *smvR* mutants (Table 1). In order to further analyze 172

Table 1. MICs of biocides and an	timicrobials for	the different	strains
----------------------------------	------------------	---------------	---------

	MIC (mg/L)												
Strains	CHX <sup>1</sup>	CV	CTAB	CB	EtBr	ACR	GEN	AMK	СТХ	CHL	ERY	NOR	TET
E. cloacae ATCC 13047	2/2	32	16	32	512	64	0.25	2	-1	8	256	0.12	1
ATCC 13047 $\Delta$ smvA	$0.5/0.5^2$	32	16	32	256	32	0.25	2	1	8	256	0.25	1
ATCC 13047 $\Delta smvR$	4/4	32	32	32	1024	64	0.25	1	1	8	256	0.12	1
ATCC 13047 pBAD202	2/2	32	16	32	512	64	0.25	2	1	8	256	0.12	1
ATCC 13047 pBAD202ΩsmvA	4/4	32	16	32	2048	256	0.12	1	1	4	256	0.12	1
ATCC 13047 pBAD202ΩsmvR	0.5/1	32	32	32	256	64	0.25	2	1	8	128	0.12	1
ATCC 13047 $\Delta acrB$	1/1	0.5	16	4	16	4	0.25	2	1	0.5	8	0.06	0.5
ATCC 13047∆acrB pBAD202	1/1	0.5	16	4	16	4	0.25	2	1	0.5	8	0.03	0.5
ATCC 13047 $\Delta acrB$ pBAD202 $\Omega smvA$	2/4	1	8	4	256	64	0.12	1	1	0.5	8	0.03	0.5
ATCC 13047 $\Delta acrB$ pBAD202 $\Omega smvR$	0.5/0.5	1	16	4	8	4	0.25	2	1	1	8	0.03	1
Cluster III													
ECL_JO04 $\Delta smvA/smvR$	0.25/0.25	64	32	32	1024	128	0.25	2	1	8	256	0.06	2
ECL_JO32	32/32	64	32	32	1024	128	0.25	2	1	8	256	0.06	2
ECL_JO32 pBAD202	32/32	64	32	32	1024	128	0.25	2	1	8	256	0.06	2
ECL_JO32 pBAD202 $\Omega$ smvA	64/64	32	32	32	2048	256	0.25	2	1	8	256	0.06	2
ECL_JO32 pBAD202 $\Omega$ smvR	4/8	32	32	32	512	64	0.25	2	1	8	256	0.06	2
Cluster VI													
ECL_JO31	16/16	32	16	16	512	64	0.12	1	1	4	256	0.06	1
ECL_JO31 pBAD202	16/16	32	16	16	512	64	0.12	1	1	4	256	0.06	1
ECL_JO31 pBAD202ΩsmvA	32/32	32	16	16	1024	128	0.12	1	1	4	256	0.06	1
ECL_JO31 pBAD202Ω-smvR	2/4	32	16	16	256	32	0.12	1	1	4	256	0.06	1
Cluster VIII													
ECL_JO38	16/16	64	32	32	1024	128	0.25	2	1	4	256	0.06	2
ECL_JO38 pBAD202	16/16	64	32	32	1024	128	0.25	2	1	4	256	0.06	2
ECL_JO38 pBAD202ΩsmvA	32/32	32	32	32	2048	256	0.25	2	1	4	256	0.06	2
ECL_JO38 pBAD202ΩsmvR	2/4	32	32	32	256	32	0.25	2	1	4	256	0.06	2

CHX : Chlorhexidine; CV: Crystal violet; CTAB: Cetyl trimethylammonium bromide; CB: Benzalkonium chloride; EtBr : Ethidium Bromide ; ACR: Acriflavine ; GEN : Gentamicin; AMK: Amikacin; CTX : Cefotaxime; CHL: Chloramphenicol ; ERY: Erythromycin; NOR : Norfloxacin;

TET : Tetracycline. <sup>1</sup> MIC/MBC <sup>2</sup> In bold are values with significant changes (>4 fold change) compared to the parental strain

the role of SmvR regulator three clinical isolates (ECL JO31, ECL JO38, and ECL JO32) 173 with higher MICs of CHX (16-32 mg/L) were also analyzed and complemented with smvR 174 cloned with its own promoter into the pBAD202 vector (Table 1). ECL\_JO32 was categorized 175 as decreased susceptibility because the MICs was < 64 mg/L. This cut-off value also 176 corresponded to the MBC and was determined for *Enterobacter* spp. based on the analysis of 177 54 clinical isolates (23). As shown in Table 1, all these strains reverted to a susceptible 178 phenotype to CHX with MICs of 2-4 mg/L. In parallel, the transcriptional levels of smvA 179 highly decreased (non-detectable) in these complemented strains (Figure 1). These results 180 strongly pointed out the role of SmvR in CHX susceptibility in E. cloacae, which are in 181 182 agreement with those observed in K. pneunoniae (22). Analysis of SmvR sequences revealed that 14 to 15 amino acids substitutions were recovered in clinical isolates compared to the 183 sequences of the two susceptible ATCC and ECL JO40 strains. Among them, 11 were at the 184 185 same positions (Figure 2A). Note that one and three substitutions were specific for ECL\_JO38 and ECL\_JO32, respectively. These data contrast with the absence of SmvR mutations in 186 187 Enterobacter sp. upon CHX exposure while it has been observed in Klebsiella, Citrobacter and Salmonella (6). Because two one substitution (G52A) was present into one of the two 188 highly conserved region of the SmvR sequence in clinical isolates, it is tempting to speculate 189 that it could play a role in high CHX MICs. We also compared the shared promotor region for 190 smvAR especially into the palindromic DYAD motifs which are typical for Tet-repressors. 191 Two interesting nucleotide-changes were identified in the sequences from clinical isolates: 192 one in the -35 box located into the well conserved motif P3, another into the P2 motif (Figure 193 2B). The impact of such modifications in decreased susceptibility to CHX needs to be further 194 studied. 195

In order to verify whether CHX may constitute an inducer of smvR expression, we measured its transcriptional level in the presence of a sub-MIC concentration of CHX (1/4 of MIC). As

shown in Figure 3, the expression of *smvR* was induced from 2.5 to 9 fold after 20, 40 and 60 198 minutes in presence of CHX in ATCC 13047, ECL\_JO32 and ECL\_JO38 strains. As for other 199 Tet-family repressors, it appears that when a signal molecule (here CHX) binds to SmvR, a 200 conformational change takes place that renders the repressor protein unable to bind DNA 201 (24). As a consequence, *smvR* (likely under its own regulation) was overexpressed (Figure 3). 202 Concomitantly, increased expression of smvA was observed in ECL JO32 and ECL JO38 203 strains but not in ATCC 13047 (Figure 4). It may be suggested that, in ATCC strain, the 204 structurally modified SmvR by CHX, may still interact with the promotor region of *smvA*. 205

## The CHX susceptibility level is not quantitatively correlated to the level of *smvA* transcription.

We showed that an almost undetectable level of *smvA* transcription led to a low MIC of CHX 208 and overexpression of *smvA* in all *Enterobacter* strains was coupled with a two fold increase 209 210 of MICs arguing for a role of SmvA (Figure 1, Table 1). However, no strict quantitative correlation between the transcriptional level of smvA and MICs were observed. Indeed, the 211 212 transcription of smvA in ECL\_JO31 (with a MIC of 16 mg/L) was 4.3 fold higher than in ECL JO38 (with also a MIC of 16 mg/L) and 2-fold lower than in *smvR* mutant of the ATCC 213 13047 strain that has a MIC of 4 mg/L (Figure 1). Likewise, we measured 3 fold more smvA 214 transcript in the *smvR* mutant of ATCC 13047 than in ECL\_JO32, whereas MIC of CHX was 215 8 fold lesser (Figure 1, Table 1). Recently, it has been shown that heterologous expression of 216 *smvA* from *K. pneumoniae* or *S. enterica* in *E. coli* (which do not possesses *smvAR* homologs) 217 modestly increased MICs of CHX (from 0.5 to 2-4 mg/L) (6). Noteworthy, contrarily to these 218 E. coli strains, we did not observe any growth defect for our ECC transconjugants (data not 219 shown). 220

Thus, in *Enterobacter*, it may be hypothesis that SmvR may have other targets than *smvA* whose products are involved in CHX reduced susceptibility. Such of targets should be

other(s) MFS-family efflux pump(s) because the addition of 20 mg/L reserpine (MFS pumps
inhibitor) dramatically reduced the MICs of CHX (2-4 mg/L) in clinical isolates and strains
overexpressing *smvA* (Table S4).

#### 226 Role of SmvA and SmvR in resistance to other biocide compounds.

We previously showed that the ArcB efflux pump of the RND family was involved in the 227 resistance of *E. cloacae* to the biocides such as BC and tetraphenylphosphonium and to the 228 dyes ACR, CV, EtBr and rhodamine (25). On the other hand, the lack of AcrB did not impact 229 the resistance to CHX or cetyltrimethylammonium bromide (CTAB) (Table 1) (25). To test 230 whether SmvA and/or SmvR can play a role in the resistance to such of molecules, MICs 231 232 were determined for the different constructions of ECC previously used as well as in transcomplemented strains of acrB mutant of Enterobacter. Towards CV, CTAB and CB, no 233 difference was observed for the smvA and smvR mutant or transcomplemented strains 234 compared to the wild-type or parental counterparts (Table 1). On the other hand, a 4-fold 235 increase of MICs to EtBr and ACR was observed when smvA was overexpressed into the 236 ATCC 13047 strain and a 4-fold decrease when smvR was overproduced in the ECLJO\_038 237 clinical isolate (Table 1). However, the most important effects were obtained when *smvA* was 238 expressed in the *acrB* mutant strain susceptible to EtBr and ACR. Indeed, complementation 239 by smvA in this mutant almost completely restored levels of resistance to EtBr and ACR until 240 those of the wild type ECC strain (Table 1). This clearly show that, according to biocide, the 241 MFS-family efflux pump SmvA was able to compensate the lack of the major RND family 242 pump AcrB. 243

#### 244 SmvA and SmvR are not involved in antibiotic resistance.

The question if biocides select for antibiotic resistance has been asked since long time (3). This possible link may be due to the selective pressure constituted by the presence of antiseptics leading to the emergence of mechanisms of resistance that are common with other

antimicrobial compounds. In this context, the overexpression of efflux pumps may be of great 248 interest. In E. cloacae, the acrB mutant is more susceptible to several biocides as well as 249 tetracyclines, cotrimoxazole, chloramphenicol, fusidic acid, fluoroquinolones, and 250 erythromycin (25). In order to evaluate the putative role of SmvA and SmvR in antibiotic 251 resistance, MICs of GEN, AMK, CTX, CHL, ERY, NOR and TET of the different strains 252 used in this study were determined. As shown in Table 1, no significant difference was 253 observed neither for smvA or smvR mutant strains or cells overproducing SmvA or SmvR 254 compared to their isogenic parental strains. In contrast to AcrB, these results argue for a minor 255 involvement of the SmvA efflux pump in the acquisition of antibiotic resistance. 256

257

#### 258 Concluding remark.

The transcriptional regulator SmvR of Enterobacter acted as repressor of the expression of 259 260 *smvA* (encoding a MFS family efflux pump). However, other(s) member(s) of its regulon may be involved in the resistance to CHX observed in some clinical isolates. In addition, the 261 overproduction of MFS-type SmvA was able to partially complement the lack of the AcrB 262 RND-family efflux pump by restoring the resistance to EtBr and ACR biocides. Despite that 263 *smvRA* locus did not seem implicated in the antimicrobial resistance of ECC, it appears as an 264 important opportunistic trait. Characterization and survey of such mechanisms enabling this 265 pathogen to cope with biocides are important especially in hospital environment to avoid the 266 emergence and persistence of virulent isolates. 267

268

#### 269 ACKNOWLEDGMENT

The authors warmly thank Michel Auzou, Sebastien Galopin, and Mamadou Godet for technical assistance. François Gravey and Marion Aubourg works are supported by grants from the Ministère de l'Enseignement Supérieur et de la Recherche and the Region 273 Normandy, respectively.

274

275 We have no relevant financial disclosures or funding to declare.

#### 277 **REFERENCES**

- Kampf G. 2018Antiseptic stewardship: biocide resistance and clinical implications. In:
   Kampf G, ed. *Antiseptic stewardship: biocide resistance and clinical implications*.
   Springer International Publishing; Cham, Switzerland 1–7.
- Cozad A, Jones RD. 2003. Disinfection and the prevention of infectious disease. *Am J Infect Control* 31:243-54.
- Russell AD. 2003. Biocide use and antibiotic resistance: the relevance of laboratory
   findings to clinical and environmental situations. *Lancet Infect Dis* 3:794-803.
- Hassan KA, Jackson SM, Penesyan A, Patching SG, Tetu SG, Eijkelkamp BA, Brown
   MH, Henderson PJ, Paulsen IT. 2013. Transcriptomic and biochemical analyses
   identify a family of chlorhexidine efflux proteins. *Proc Natl Acad Sci U S A*.
   110(50):20254-9. doi: 10.1073/pnas.1317052110
- 5. Fang CT, Chen HC, Chuang YP, Chang SC, Wang JT. 2002. Cloning of a cation
   efflux pump gene associated with chlorhexidine resistance in *Klebsiella pneumoniae*.
   *Antimicrob Agents Chemother* 46:2024-8.
- Wand ME, Jamshidi S, Bock LJ, Rahman KM, Sutton JM. 2019. SmvA is an
   important efflux pump for cationic biocides in *Klebsiella pneumoniae* and other
   *Enterobacteriaceae*. Sci Rep 9:1344. doi:10.1038/s41598-018-37730-0.
- 7. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J,
  Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and
  outcomes of infection in intensive care units. *JAMA* 302:2323-9. doi:
  10.1001/jama.2009.1754.
- 8. Hoffmann H, Roggenkamp A. 2003. Population genetics of the nomenspecies
   *Enterobacter cloacae*. *Appl. Environ. Microbiol* 69:5306-5318.

- Morand PC, Billoet A, Rottman M, Sivadon-Tardy V, Eyrolle L, Jeanne L, Tazi A,
   Anract P, Courpied JP, Poyart C, Dumaine V. 2009. Specific distribution within the
   *Enterobacter cloacae* complex of strains isolated from infected orthopedic implants. J
   *Clin Microbiol* 47:2489-95. doi: 10.1128/JCM.00290-09.
- 10. Beyrouthy R, Barets M, Marion E, Dananché C, Dauwalder O, Robin F, Gauthier L, 305 Jousset A, Dortet L, Guérin F, Bénet T, Cassier P, Vanhems P, Bonnet R. 2018. Novel 306 leading cause of nosocomial outbreak involving Enterobacter lineage as 307 carbapenemase-producing Infect Dis 24:1505-1515. strains. Emerg 308 doi:10.3201/eid2408.180151. 309
- 11. Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE
  pathogens. *Expert Rev Anti Infect Ther* 11:297-308. doi:10.1586/eri.13.12.
- 312 12. Ren Y, Ren Y, Zhou Z, Guo X, Li Y, Feng L, Wang L. 2010. Complete genome
  313 sequence of *Enterobacter cloacae* subsp. *cloacae* type strain ATCC 13047. *J Bacteriol*314 192:2463-4. doi: 10.1128/JB.00067-10.
- 315 13. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in
   316 *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640-5.
- 317 14. Derbise A, Lesic B, Dacheux D, Ghigo JM, Carniel E. 2003. A rapid and simple
   318 method for inactivating chromosomal genes in *Yersinia*. FEMS *Immunol Med* 319 *Microbiol* 38:113-6.
- 320 15. Guérin F, Isnard C, Cattoir V, Giard JC. 2015. Complex regulation pathways of
   321 AmpC-mediated β-lactam resistance in *Enterobacter cloacae* complex. *Antimicrob* 322 Agents Chemother 59:7753-61. doi: 10.1128/AAC.01729-15.
- 16. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina
   sequence data. *Bioinformatics* 30:2114-20. doi:10.1093/bioinformatics/btu170.

325	17. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM,
326	Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G,
327	Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and
328	its applications to single-cell sequencing. J Comput Biol 19:455-77. doi:
329	10.1089/cmb.2012.0021.

- 18. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup
   FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J
   Antimicrob Chemother 67:2640-4. doi: 10.1093/jac/dks261.
- 19. Kampf G. 2016. Acquired resistance to chlorhexidine is it time to establish an
  'antiseptic stewardship' initiative? *J Hosp Infect* 94:213-27. doi:
  10.1016/j.jhin.2016.08.018.
- 20. Pastrana-Carrasco J, Garza-Ramos JU, Barrios H, Morfin-Otero R, Rodríguez-Noriega
  E, Barajas JM, Suárez S, Díaz R, Miranda G, Solórzano F, Contreras J, Silva-Sánchez
  J. 2012. [QacEdelta1 gene frequency and biocide resistance in extended-spectrum
  beta-lactamase producing *enterobacteriaceae* clinical isolates]. *Rev Invest Clin*64:535-40.
- Kücken D, Feucht H, Kaulfers P. 2000. Association of *qacE* and qacEDelta1 with
   multiple resistance to antibiotics and antiseptics in clinical isolates of Gram-negative
   bacteria. *FEMS Microbiol Lett* 183:95-8.
- Wand ME, Bock LJ, Bonney LC, Sutton JM. 2016. Mechanisms of increased
   resistance to chlorhexidine and cross-resistance to colistin following exposure of
   *Klebsiella pneumoniae* clinical isolates to chlorhexidine. *Antimicrob Agents Chemother* 61:e01162-16. doi: 10.1128/AAC.01162-16.
- Morrissey I, Oggioni MR, Knight D, Curiao T, Coque T, Kalkanci A, Martinez JL.
   2014. Evaluation of epidemiological cut-off values indicates that biocide resistant

350	subpopulations	are	uncommon	in	natural	isolates	of	clinically-relevant
351	microorganisms.	PLoS	One 9:e86669	). doi	: 10.1371	/journal.po	ne.00	)86669.

- 24. Ramos JL, Martínez-Bueno M, Molina-Henares AJ, Terán W, Watanabe K, Zhang X,
  Gallegos MT, Brennan R, Tobes R.. 2005. The TetR family of transcriptional
  repressors. *Microbiol Mol Biol Rev* 69:326-56.
- 355 25. Guérin F, Lallement C, Isnard C, Dhalluin A, Cattoir V, Giard JC. 2016. Landscape of
   356 Resistance-Nodulation-cell Division (RND)-type efflux pumps in *Enterobacter* 357 *cloacae* complex. *Antimicrob Agents Chemother* 60:2373-82. doi:
- 358 10.1128/AAC.02840-15.
- 359

#### 361 FIGURE LEGENDS

362

Figure 1: Expression ratios of *smvA* in ATCC 13047, *smvA* mutant, *smvR* mutant, clinical isolates and complemented strains by pBAD $\Omega$ 0-*smvR*. Asterix indicates *p*-value < 0.05 compared to the data obtained with the ATCC 13047 strain.

366

**Figure 2:** Sequence alignments of SmvR (A) and *smvR-smvA* intergenic region (B). (A) In bold are the amino acids substitutions compared to the sequences of the two susceptible strains ATCC 13047 and ECL\_JO40. Conserved regions in *Enterobacteriaceae* in SmvR proteins are indicated in boxes. (B) Potential conserved motifs P2 and P3 are in boxes. Grey boxes indicate start codons of *smvR* and *smvA* ORFs. Putative -10 and -35 boxes are indicated in italic. Putative interesting nucleotide changes are in bold.


373

Figure 3: Expression ratios of the *smvR* gene in ATCC 13047 and clinical isolates without and with  $\frac{1}{4}$  MIC of CHX during 20, 40 and 60 minutes. Asterix indicates *p*-value < 0.05 compared to the data obtained with the ATCC 13047 strain without CHX.

377

Figure 4: Expression ratios of the *smvA* gene in ATCC 13047 and clinical isolates without and with  $\frac{1}{4}$  MIC of CHX during 20, 40 and 60 minutes. Asterix indicates *p*-value < 0.05 compared to the data obtained with the ATCC 13047 strain without CHX.

- 381
- 382
- 383




**Figure 1**: Expression ratios of *smvA* in ATCC 13047, *smvA* mutant, *smvR* mutant, clinical isolates and complemented strains by pBAD202 $\Omega$ *smvR*. Asterix indicates *p*-value <0.05 compared to the data obtained with the ATCC 13047 strain.


Α

ATCC13047 MGYLTRDERREEILQAAMRVALAEGFSAMTVRRIASEAGVATG <u>QVHHHFTSGGELK</u> SLAFIRLIRELLDADVVGEHASWRARLHAMLGSDDGRFEPYIRLWREAQILATRDAEIKGAYVL ECL_JO40 MRYLSKEERREAILQAAMRVALSEGLAAMTVRRIAAEAGVATGQVHHHFASGGELKSLAFVRVIRELLDAEVVGENASWRARLHAMLGSDDGGFEPYIRLWREAQILASRDPEIKAAYVL ECL_JO31 MRYLSKDERREEILQAAMRVALTEGFAAMTVRRIATEAGVATGQVHHHFASAGELKSLAFVRVIRELLDAEVVGENAGWRERLHAMLGSDDGGFEPYIRLWREAQILASRD <b>SD</b> IKGAYVL ECL_JO32 MRYLSKDERREEILHAAMRVALSEGLSAMTVRRIATEAGIATGQVHHHFASAGELKSLAFVRLIRNLLDAEIVGENAGWRERLHAMLGSDDGGFEPYIRLWREAQILASRDSDIKGAYVL ECL_JO38 MRYLSKDERREEILHAAMRVALSEGLSAMTVRRIATEAGVATGQLHHHFASAGELKSLAFVRLIRDLLDAEIVGENAGWRERLHAMLGSDDGGFEPYIRLWREAQILASRDSDIKGAYVL
ATCC13047TMEMWHQETVALIEAGRNAGVFRSGDPAASIAWRLIGLVCGLDGIYLLNMPEMDDAAFNNHLDKLISLELF191ECL_J040TMEMWHQETVAIIRAGATACAFTLNDRAENIAWRLIGLVCGLDGITILNMPEMDDAAFNKHLDKLISLELF191ECL_J031TMEMWHQETVAIIRAGAEANAFTLADQPENIAWRLIGLVCGLDGIYVLNMPEMDDAAFNKHLDKLISLELF191ECL_J032TMEMWHQETVAIIRAGAEANAFTLADQPENIAWRLIGLVCGLDGIYVLNMPEMDDAAFNKHLDKLISLELF191ECL_J038TMEMWHQETVAIIRAGAEANAFTLADQPENIAWRLIGLVCGLDGIYVLNMPEMDDAAFNKHLDKLISLELF191
В
-10       P3       -35       P2         ATCC3047 <smvr< td="">       CAT       TTTCTCTCACTCTTAAATAGCAATGAAACGAGTGTAACAAAGAGCTGGACAAGTGTTCAACA       TTCCGTAGGATCGCATCCTGGACATGTG         ECL_J040       <smvr< td="">       CAT       TTTTTTTCTACTCTC.AATGGGAATGAAACGAGTGTAACAAAAGCTGGACATGCGTTCAACA       TTCCGTAGGATCGCATCCTGGACATGTG         ECL_J031       <smvr< td="">       CAT       AATTTCTCACTCTC.AATGGCAACGAAGGGTGTAACAAAGAGCTGGACAAGTGTTCAACTTTACGTAGGATCGCAATCTGGACATGTG         ECL_J032       <smvr< td="">       CAT       ATTTCCTCACTCTC.AATGGCAACGAAGGAGTGTAACAAAGAGCTGGACAAGGGTTCAACTTTACGTAGGATCGCAATCTGGACATGTG         ECL_J038       <smvr< td="">       CAT       AATTTCTCACTCTC.AATGGCAACGAAGGAGTGTAACAAAGAGCTGGACAAGTGTTCAACTTTACGTAGGATCGCAATCTGGACATGTG         ****::*       ****::*       ****::*       ****::*       ****::**       ****:****         ATCC3047       TCCA.TTTTTA.TATAAAAAGGAAATTTAATG&gt;       smvA</smvr<></smvr<></smvr<></smvr<></smvr<>
AICCSU47 TCCATTATATATAAAAGGAAATTTATG> SMVA         ECL_JO40 TCCATGAAAGGAAATGATAAGGAAATTTATG> SmvA         ECL_JO31 TCCAGTTTTT.AAATGAAAAGGAAATTTATG> SmvA         ECL_JO32 TCCAGTTTTT.AACTGAAAAGGAAATTTATG> smvA         ECL_JO38 TCCAATTTTT.AACTGAAAAGGAAATTTATG> smvA         ***** ****: :.*.***********************

**Figure 2**: Sequence alignments of SmvR (A) and *smvR-smvA* intergenic region (B). (A) In bold are the amino acids substitutions compared to the sequences of the two susceptible strains ATCC 13047 and ECL\_JO40. Conserved regions in *Enterobacteriaceae* in SmvR proteins are boxed. (B) Potential conserved motifs P2 and P3 are in boxes. Grey boxes indicate start codons of *smvR* and *smvA* ORFs. Putative -10 and -35 boxes are indicated in italic. Putative interesting nucleotide changes are in bold.



**Figure 3**: Expression ratios of the *smvR* gene in ATCC 13047 and clinical isolates without and with <sup>1</sup>/<sub>4</sub> MIC of CHX during 20, 40 and 60 minutes. Asterix indicates *p*-value <0.05 compared to the data obtained with the ATCC 13047 strain without CHX.



**Figure 4**: Expression ratios of the *smvA* gene in ATCC 13047 and clinical isolates without or with <sup>1</sup>/<sub>4</sub> MIC of CHX during 20, 40 and 60 minutes. Asterix indicates *p*-value <0.05 compared to the data obtained with the ATCC 13047 strain without CHX.